STM JOURNALS

Research & Reviews: A Journal of
Pharmacology

https://journals.stmjournals.com/rrjop

ISSN: 2230-9861 (Online)
ISSN: 2349-1299 (Print)
Volume 14, Issue 1, 2024
January–April
DOI (Journal): 10.37591/RRJoP

Review RRJoP

Investigation of Migraine

Sachin R. Gosavi, Vaishnavi D. Patil*

Abstract

Individual's medical history, and any potential side effects should be considered. It is also important to consult with a healthcare provider before beginning any new treatment plan, as they can provide guidance on the best course of action based on the individual's specific needs and circumstances. In addition to medication, individuals with migraines can explore various treatment avenues. Lifestyle modifications, such as incorporating regular exercise, maintaining a healthy diet, managing stress through relaxation techniques, and ensuring adequate sleep, are all vital components to enhance overall well-being and potentially reduce migraine frequency and intensity. These may encompass various stress management techniques like meditation or yoga, dietary modifications such as avoiding trigger foods, and incorporating regular exercise into one's routine. Additionally, alternative therapies like acupuncture and biofeedback have emerged as promising adjuncts to conventional treatments in alleviating migraine symptoms, offering patients additional avenues for relief and a more comprehensive approach to managing their condition. Effectively managing migraines necessitates a holistic strategy that considers the individual's overall well-being and habits. This comprehensive approach involves addressing not only the physical symptoms but also the mental and emotional aspects, lifestyle factors, and any underlying health conditions to achieve optimal results in migraine management. By staying informed about current trends and developments in migraine treatment, individuals can work with their healthcare providers to create a personalized treatment plan that effectively manages their symptoms and improves their quality of life.

Keywords: Analysis of acute migraine, chronic migraine, headache, medication overuse headache, with aura and without aura

INTRODUCTION

Tension-type headache is another prevalent headache disorder, often described as a continuous band-like pressure or tightness around the head. Cluster headache is a relatively rare but extremely severe type of headache, characterized by excruciating, unilateral pain around the eye, temple, or forehead, often accompanied by autonomic symptoms such as nasal congestion, tearing, and eye redness.

Despite the significant impact that headache disorders can have on daily life, they are often underdiagnosed and undertreated. This can lead to unnecessary suffering and decreased quality of life for individuals affected by these conditions. It is important for healthcare providers to properly diagnose and manage headache disorders in order to improve the well-being of those who experience them.

In this review, we will discuss the epidemiology, clinical features, pathophysiology, and treatment options for the most common primary headache disorders. By increasing our understanding of these conditions, we can help to improve the quality of care provided to individuals living with headache disorders [1, 2].

***Author for Correspondence**
Vaishnavi D. Patil
E-mail: vp056205@gmail.com

Student, Department of Pharmacognosy, Ahinsa Institute of Pharmacy, Dondaicha, Maharashtra, India

Received Date: March 11, 2024
Accepted Date: March 28, 2024
Published Date: April 20, 2024

Citation: Sachin R. Gosavi, Vaishnavi D. Patil. Investigation of Migraine. Research & Reviews: A Journal of Pharmacology. 2024; 14(1): 38–45p.

- *Step 1:* When to suspect migraine: Some of the signs and symptoms to look out for include mild to severe headaches, which are usually one-sided, throbbing, and body aches. Other symptoms may include aura symptoms such as nausea, vomiting, sensitivity to light or sound, and changes in vision or hearing. In patients with recurrent symptoms, especially if there is a family history of migraine or frequent headaches, it is important to suspect migraine as it affects daily work.
- *Step 2:* Diagnosis according to ICHD-3: To diagnose migraine without aura, at least five headaches lasting 4–72 h must occur and have certain features such as solitary confinement, physical activity, and daily physical activity. Similar conditions apply to migraine with aura, in addition to the presence of recurrent visual, sensory or speech disturbances before the onset of the headache. Chronic migraine is diagnosed if headaches occur for 15 days, more a month or for more than 3 months and at least half of them meet migraine criteria.
- *Step 3:* Differential diagnosis: It is important to distinguish migraine from other headaches, such as headaches or migraines, and other headaches including those caused by brain tumors, infections or nerves. This can be done with a good history, physical examination, and possibly imaging studies or other tests as needed.

In summary, being able to consider migraine as a medical condition, using correct diagnostic criteria and distinguishing it from other headaches is important in terms of providing appropriate treatment to migraine patients and improving the quality of life. If migraine is suspected, it is recommended to consult a doctor for further evaluation and treatment [3].

Migraine Without Aura

Migraine without aura is a psychological disease that affects individuals with recurring headaches that last between 4 and 72 h. These attacks are usually localized, pulsating in nature, and are characterized by moderate to severe pain. Daily physical activity may worsen symptoms during an attack. It is important for people suffering from migraine without aura to receive diagnosis and treatment from a doctor for better control and reduction of symptoms [4, 5].

Migraine with Aura

It may cause visual disturbances, such as flashes of light or blindness, or physical symptoms, such as tingling or numbness. Some people may also experience speech problems or confusion during the aura. These symptoms usually last between 20 min and an hour and vary from person to person. It is important to remember that not all migraine patients experience an aura, and those who do not experience it with every attack. Understanding and recognizing aura symptoms can help people effectively manage and treat migraines [4].

In some cases, these symptoms may also appear as a burning or tingling sensation that can last from a few minutes to several hours. Others may be sensitive to touch or warmth of the affected area. These allergic reactions may vary in intensity and may come and go from time to time. In general, many of the symptoms of emotional pain in affected individuals demonstrate the complexity of this condition and the importance of individual treatment [6].

Chronic Migraine

There is no control or maintenance. It is important for people with migraines to work with their doctors to develop a personalized treatment plan that includes a combination of medication, lifestyle changes and exercise, medical or other treatments. By managing chronic migraine, people can reduce the frequency and severity of symptoms, improve overall quality of life, and potentially reduce the risk of migraine recurrence [7]. The exact cause of migraine is not fully understood, but there is believed to be a connection between genetics, the environment and the nervous system. Some factors that trigger migraines include stress, hormonal changes, certain foods, and changes in sleep patterns. Migraine pain can be excruciating and often feels like ringing or buzzing on one side of the head. Other symptoms

include nausea, vomiting, sensitivity to light and sound, and vision changes. Migraines can last from a few hours to a few days and can affect a person's quality of life. Treatment of migraine usually includes lifestyle changes, avoiding triggers, and medications to control symptoms. Some people may find help from alternative treatments such as acupuncture, massage, or nutritional supplements. It is important for people with migraines to work with their doctors to develop a personalized treatment plan that meets their specific needs and helps minimize the effects of this disease [8].

These attacks can last for hours or even days and cause severe pain such as nausea, vomiting, sensitivity to light and sound, and dizziness. The exact causes of migraines are not fully understood, but research suggests that genetic and environmental factors play a role.

Migraines can be caused by many things, including certain foods, stress, hormonal changes, and changes in sleep patterns. Migraine treatment usually includes lifestyle changes, such as avoiding and managing stress, as well as medications to help reduce symptoms and prevent future attacks. Although there is no cure for migraine, there are many ways to treat it, control the situation and improve the quality of life of affected people. Seeking medical advice and working closely with a doctor to develop a personalized treatment plan can help people better manage migraines and reduce attacks and their severity [9, 10].

PRECLINICAL STUDIES OF CHRONIC MIGRAINE

Migraine Symptomatology

Migraine manifests as a pulsating flank headache that is often accompanied by sensitivity to light, sound, and smell, nausea, vomiting, strong scalp reaction, and discomfort during exercise. These adverse attacks usually last from 4 to 72 h [11].

A deeper understanding of these factors allows us to view migraine as an integrated disease involving multiple cortical, subcortical, and brain regions. This complex interaction causes many signs and symptoms in migraine patients [12].

Approximately one-third of migraineurs may have a migraine aura associated with neurological disorders such as visual disturbances, paresthesia, speech/language problems, or movement problems. These symptoms may occur before or during the headache [13].

Pathophysiology

There is ample evidence supporting the involvement of the diencephalic and brainstem nuclei in controlling and regulating the trigeminal vascular activation process. These findings suggest that these brain regions play an important role in regulating activation of the trigeminal vasculature and highlight their importance in perception and function [14, 15].

A network of nerves called the trigeminal vascular system plays an important role in sensation in the head. This system includes the best projections that carry signals to the nerves of the head and the ideal projections that carry messages to the trigeminal nucleus caudalis. When this process is activated, many reactions occur, such as meningeal vasodilation, neurogenic inflammation and central sensitization. Finally, these situations lead to the feeling of headache [16, 17].

Activation of trigeminal afferents is initiated by the opening of neuronal pannexin-1 megachannels, leading to subsequent activation of caspase-1. This activation cascade leads to the release of various proinflammatory mediators. Additionally, it induces the activation of NFkB (nuclear factor kappaB), resulting in the spread of inflammatory signals to the trigeminal nerve fibers around the leptomeningeal nerve [18].

This leads to disruption of cortical, meningeal and brainstem events leading to pain-sensitive meningeal inflammation and headache through central and peripheral mechanisms [19, 20]. This process not only

increases the sensitivity of the trigeminal nerve to pain, but also causes the release of inflammatory mediators and aggravation of the headache. Understanding the interaction between cortical inhibition and trigeminal nociception is important for developing migraine treatment plans. By uncovering these mechanisms, researchers can identify new drug targets that will eliminate these disorders and provide relief to migraine patients. In addition, studying this process will also help in the future to better understand the treatment of other diseases that affect hearing function and pain in the brain [21].

Pain perception and transmission in migraineurs: Additionally, research has elucidated the role of neurotransmitters such as serotonin and dopamine in regulating the neurochemical imbalances associated with migraine attacks. In addition, advances in neuroimaging technology have enabled the determination of structural and functional changes in the brains of migraine patients. People with migraine report the course of the disease. This deeper understanding paves the way for the development of targeted interventions, including new drugs that specifically target brain dysfunction in migraine pathogenesis. Overall, the integration of discovery research with clinical practice has revolutionized migraine treatment by offering patients better outcomes and the possibility of self-healing. As our understanding of migraine pathophysiology continues to expand, we can expect more clinical interventions that will improve the quality of life for millions of people living with this disease [22, 23].

MIGRAINE PREVENTION

If migraine occurs frequently or the patient exhibits severe symptoms or persistent aura, it is recommended to consider preventing migraine with education and behavioral therapy. When choosing an anti-migraine medication, several factors need to be taken into account, such as the frequency of attacks (e.g., chronic pain), the presence of comorbidities, and the specific needs of the patient. Studies have shown the effectiveness of many medications in preventing migraines, including beta blockers such as metoprolol and propranolol, anticonvulsants such as the calcium antagonist flunarizine, topiramate and valproic acid, and the antidepressant Amitriptyline. Note that due to potential risks, valproic acid is contraindicated in women of childbearing potential. Additionally, other medications such as bisoprolol, lisinopril, and candesartan are promising but need further research. Medications such as topiramate and botulinum toxin type A for chronic migraine have proven effective, especially when combined with non-pharmacological treatments such as behavioral techniques such as relaxation techniques. Regular participation in aerobic endurance exercise is also recommended as part of the migraine management plan. Patients whose quality of life is reduced due to migraine can benefit from psychotherapy focusing on coping strategies, stress management and relaxation techniques.

TREATMENT

Although significant advances have been made in the treatment of migraine with the introduction of triptans, it should be acknowledged that these drugs may not be effective in every patient. Therefore, the main breakthrough in migraine treatment will involve the development of treatment for severe attacks that do not affect nerves, but only pain-related neurons. More importantly, if the theory that neurogenic inflammation causes migraines is correct, developing specific drugs that target the peripheral nervous system and prevent vascular involvement could be very effective in reducing migraine symptoms in migraine patients [24].

Ergot Alkaloids: Ergotamine

Ergotamine, a compound derived from the ergot fungus, was initially discovered and isolated by the Scottish chemist named Storr. This significant discovery paved the way for further research into the pharmacological properties of ergotamine and its potential medical applications. Storr's work has had a lasting impact on the understanding of this compound's bioactivity [25].

Since 1926, this method has been regularly employed in the immediate alleviation of migraine symptoms. Given its effectiveness in managing severe headaches, it continues to be a popular choice among healthcare professionals for treating acute migraine episodes [26].

Like dihydroergotamine mesylate, ergotamine interacts with many receptors, including 5HT, dopamine, and norepinephrine receptors. This broad interaction causes ergotamine to alter many neurotransmitter systems and affect many physiological processes in the body. Ergotamine binds to these receptors and exerts its effects on vasoconstriction, nociception and neurotransmitter release. The interaction between ergotamine and this type of receptor contributes to its clinical use and explains its effectiveness in the treatment of migraines and headaches [27].

Due to its effect on primary metabolism, ergotamine offers a minimum bioavailability of less than 1% when taken orally, while the drug reaches a recommended bioavailability of 100% when taken up by blood vessels. This small difference reflects the difficulty of achieving the optimal effect of ergotamine when administered orally [28].

The bioavailability of ergotamine suppositories when administered rectally is generally between 1 and 3%. After absorption, ergotamine is metabolized in the liver and its metabolites are excreted in bile. The elimination half life is short, approximately 2 h. The liver plays an important role in the metabolism of ergotamine, which determines its overall pharmacokinetics. Additionally, biliary excretion of ergotamine metabolites demonstrates the body's natural mechanism for removing this compound and demonstrates the complex process of its clearance from the system [29].

The potential for adverse drug reactions is increased due to ergotamine's limited ability to select target receptors. Animal studies indicate that the vasoconstrictive effects of ergotamine are primarily in the carotid vasculature. This causes blood flow to be restricted to certain areas, with only a minor change in circulation to other tissues, such as the brain [30, 31].

In humans, ergotamine causes vasoconstriction in pulmonary, cerebral, and coronary arteries. This contraction causes blood flow and oxygen to vital organs to decrease, which can cause symptoms such as chest pain, shortness of breath, and even cerebral ischemia due to decreased blood flow to the brain [32, 33].

Ergotamine, a medication used to treat migraines, works by causing coronary artery narrowing. Narrowing of the arteries reduces blood flow to the heart, leading to ischemic changes. In patients with existing coronary artery disease, this may present as angina, a condition characterized by chest pain or discomfort [34].

Triptans

Ergotamine, a medication used to treat migraines, works by causing coronary artery narrowing. Narrowing of the arteries reduces blood flow to the heart, leading to ischemic changes. In patients with existing coronary artery disease, this may present as angina, a condition characterized by chest pain or discomfort [35]. Additionally, the mechanism of action of triptans interferes with the activity of 5HT1D receptors, affecting the release of vasoactive peptides that cause neurogenic pain. This effect occurs centrally, and triptans block the transmission of nociceptive signals back to the trigeminal nucleus caudalis, thus reducing the pain associated with diseases such as migraine [36, 37].

NSAIDs in the Acute Treatment of Migraine

Aspirin, acetaminophen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac, and naproxen are often used to treat headaches (including migraines) because of their anti-inflammatory properties. It is important to remember that although acetaminophen may be slightly more effective in treating migraines than other nonantibiotic medications, proper dosage and timing are important to maintain good results. If clinical outcomes are adversely affected by reduced absorption due to gastroparesis, consideration of prokinetic drugs or other routes of administration (e.g., rectal or parenteral) is warranted. It is important to solve this problem. In an emergency situation, intramuscular injection is also an important option for rapid treatment.

When choosing the appropriate NSAID for migraine treatment, factors such as rapid absorption from the intestine, balance between effectiveness and side effects should be prioritized. In this case, drugs such as aceclofenac, diclofenac, ibuprofen, indomethacin and naproxen are suitable candidates. For people who cannot tolerate traditional NSAIDs, cyclooxygenase2 (COX2) inhibitors are a preferred alternative. Additionally, triptans are recommended treatment options when NSAIDs alone are not sufficient to relieve migraine symptoms, especially in severe migraines. The combination of oral triptans with non-steroidal anti-inflammatory drugs has been shown to increase clinical efficacy. Additionally, careful use of non-steroidal anti-inflammatory drugs may be considered as appropriate medical care during migraine detoxification [38, 39].

Ibuprofen belongs to the group of propionic acid derivatives and is a popular choice for combating migraines. The recommended dosage for effectiveness is usually 800–1,200 mg, or 400 mg when used as the arginine salt. Importantly, these doses have consistently been shown to be effective compared to placebo in treating migraine, thus reinforcing ibuprofen's position as a safe and effective pain treatment [40, 41]. Lower doses in the form of liquid gel formulations ranging from 200 to 600 mg have been found to be effective in achieving the desired results. This demonstrates the effectiveness of that management system [42]. Like the regular 200 and 400 mg versions, the extended-release version provides a similar dose, allowing greater release of the active ingredient into the bloodstream and providing long-term effects [43]. Clinical studies show that 400 mg of ibuprofen is not as effective as 10 mg of rizatriptan when improved with placebo. Despite the difference in effectiveness, both drugs provide some relief to patients, with rizatriptan working better [44]. Sumatriptan 50 mg is known to be effective in reducing migraine symptoms and its effectiveness in treating migraines is widely recognized [45].

CONCLUSION

Migraine treatment is a complex and multifaceted process. In addition to pharmacological interventions for severe pain, there is awareness of the importance of identifying and integrating non-pharmacological strategies such as lifestyle changes and behavioral and preventive pharmacotherapy. Despite advances in the treatment of severe migraine, the needs are still not met because not all patients respond adequately to existing treatments. However, there is hope for the future as research into the mechanisms underlying migraine continues, promising to develop new and better treatments to improve outcomes that will benefit people suffering from this debilitating disease.

REFERENCES

1. WHO. (2024 Mar 6). Migraine and other headache disorders. [Online]. WHO. Accessed March 20, 2024. https://www.who.int/news-room/fact-sheets/detail/headache-disorders
2. Gordon-Smith K, et al. Rapid cycling as a feature of bipolar disorder and comorbid migraine. J Affect Disord, Elsevier. 2015; 175: 320–4. Available from: http://dx.doi.org/10.1016/j.jad.2015.01.024
3. Arnold M. Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia. 2018; 38(1): 1–211.
4. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, (beta version). Cephalalgia. 2013 Jul; 33(9): 629–808.
5. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population–a prevalence study. J Clin Epidemiol. 1991; 44(11): 1147–1157.
6. Olesen J. The international classification of headache disorders. Headache: The Journal of Head and Face Pain. 2008 May; 48(5): 691–3.
7. Serrano D, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017; 18(1): 101.
8. Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice. 2nd edition. Florence, KY: Taylor & Francis; Martin Dunitz; 2002

9. Lance JW, Goadsby PJ. Mechanism and management of headache. 6th Edn. Boston: Butterworth–Heinemann; 1998.
10. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford, England: Isis Medical Media; 1998.
11. Headache Classification Committee of the International Headache Society (HIS). The International Classification of Headache Disorders. 3rd Edn. (beta version). Cephalalgia. 2013; 33(9): 629–808.
12. Charles A. Migraine: a brain state. Curr Opin Neurol. 2013; 26(3): 235–239.
13. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992; 12(4): 221–228.
14. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017; 97(2): 553–622. doi: 10.1152/physrev.00034.2015.
15. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12(10): 570–584. doi: 10.1038/nrn3057.
16. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol. 2009; 65(5): 491–498. doi: 10.1002/ana.21691.
17. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003; 4(5): 386–398. doi: 10.1038/nrn1102.
18. Karatas H, Erdener SE, Gursoy-Ozdemir Y, Lule S, Eren-Koçak E, Sen ZD, Dalkara T. Spreading depression triggers headache by activating neuronal Panx1 channels. Science. 2013 Mar 01; 339(6123): 1092–5.
19. Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019 Dec 23; 20(1): 117.
20. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002 Feb; 8(2): 136–42.
21. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, Wang X, Rosenberg GA, Lo EH, Moskowitz MA. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004 May; 113(10): 1447–55.
22. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017; 97(2): 553–622.
23. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011 Oct; 12(10): 570–84.
24. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307–11.
25. Stoll A. Zur Kenntnis der Mutterkornalkaloide. Verhand der Schweiz Naturf Ges. 1920; 190: 221.
26. Maier HW. L'ergotamine, inhibiteur du sympathiqueétudié en clinique, commemoyend'explorationetcomme agent thérapeutique. Rev Neurol. 1926; 33: 1104–8.
27. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000; 123(Pt 1): 9–18. doi: 10.1093/brain/123.1.9.
28. Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986; 30(3): 331–334. doi: 10.1007/BF00541538.
29. Tfelt-Hansen PJE. Ergotamine. In: Olesen JT-HP, Welch KM, editors. The headaches. New York: Raven Press; 1993; 313–322.
30. Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol. 1978; 63(3): 541–549. doi: 10.1111/j.1476-5381.1978.tb07810.x.
31. De Vries P, Villalon CM, Heiligers JP, Saxena PR. Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors. Br J Pharmacol. 1998; 123(8): 1561–1570. doi: 10.1038/sj.bjp.0701770.

32. Cortijo J, Marti-Cabrera M, Bernabeu E, et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol. 1997; 122(7): 1455–1463. doi: 10.1038/sj.bjp.0701509.
33. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998; 98(1): 25–30. doi: 10.1161/01.CIR.98.1.25.
34. Galer BS, Lipton RB, Solomon S, Newman LC, Spierings EL. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache. 1991; 31(7): 446–450. doi: 10.1111/j.1526-4610.1991.hed3107446.x.
35. Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci. 1989; 10(5): 200–204. doi: 10.1016/0165-6147(89)90238-1.
36. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine—new insights. Can J Neurol Sci. 1999; 26(Suppl 3): S12–S19. doi: 10.1017/S0317167100000147.
37. Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005; 115(1–2): 1–4. doi: 10.1016/j.pain.2005.03.008.
38. Alahurula V, Myllyla VV, Hokkanen E, Tokola O. Tolfenamic acid and ergotamine abuse. Headache. 1981; 21(6): 240–242.
39. Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache. 1987; 27(3): 130–133.
40. Havankakanniainen H. Treatment of acute migraine attack—Ibuprofen and placebo compared. Headache. 1989; 29(8): 507–509.
41. Sandrini G, Franchini S, Lanfranchi S, Granella F, Manzoni GC, Nappi G. Effectiveness of ibuprofen-arginine in the treatment of acute migraine attacks. Int J Clin Pharm Res. 1998; 18(3): 145–150.
42. Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF, Wilkes K, Furey SA, Subramanian T, Cooper SA. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000; 20(4): 233–243.
43. Codispoti JR, Prior MJ, Fu M, Harte CM, Nelson EB. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache. 2001; 41(7): 665–679.
44. Misra UK, Kalita J, Yadav RK. Rizatriptanvs. ibuprofen in migraine: A randomised placebo-controlled trial. J Headache Pain. 2007; 8(3): 175–179.
45. Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Gobel H, Hartung E, Jimenez MD, Lange R, Manzoni GC, Mueller-Schwefe G, Nappi G, Pinessi L, Prat J, Puca FM, Titus F, Voelker M. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24(11): 947–954.

